Why the study?
Does captopril alter blood levels of angiotensin I, plasma renin activity, and bradykinin in normal Sprague-Dawley rats?
Does captopril alter blood levels of angiotensin I, plasma renin activity, and bradykinin in normal Sprague-Dawley rats?
Captopril primarily acts by inhibiting the circulating renin-angiotensin system, with an added effect on the kallikrein-kinin system at higher doses.
Answers are grounded in this paper and cite their sources.
These rat data support primary RAS inhibition by captopril; human bradykinin effects at therapeutic doses remain untested.
Captopril (SQ 14225), a new orally acting angiotensin-converting enzyme (kininase II) inhibitor, was administered by gavage to normal Sprague-Dawley rats in doses of 1 mg/kg, 3 mg/kg, and 30 mg/kg. Dose-dependent increases in blood levels of angiotensin I and in plasma renin activity occurred while the blood level of bradykinin showed a significant (twofold) rise only at the highest dose of Captopril. Endogenous angiotensin I and bradykinin achieved peak blood levels about 30 minutes after treatment. Blood levels of bradykinin then fell to normal within 60 minutes, but the elevation of blood angiotensin I level was more sustained in keeping with the slower rise and fall of plasma renin level. In normal rats, therefore, Captopril acts to inhibit the renin-angiotensin system and to potentiate the kallikrein-kinin system. Both of these actions may result in vasodilatation and a vasodepressor response. The differential effect on the two systems indicates that the antihypertensive effect of Captopril which is seen clinically is likely to be due to its action on the circulating renin-angiotensin system. However, at the upper end of the clinical dose range, an augmented response may result from an added effect on the kallikrein-kinin system.
No takes yet. Share an insight, caveat, or question.
Matthews et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: